YK
Roles
Therapeutic Areas
Kissei Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Uprifosbuvir (K-579) | Erectile Dysfunction | Approved |
| KRP-297 (Mirogabalin) | Diabetic Peripheral Neuropathic Pain (DPNP) | Phase III |
| KRP-203 (Amiselimod) | Ulcerative Colitis | Phase II |
| K-878 | Constipation-predominant Irritable Bowel Syndrome (IBS-C) | Phase II |
| K-117 | Chronic Kidney Disease with Renal Anemia | Phase II |
| K-321 | Post-cataract surgery inflammation & pain | Phase II |
Leadership Team at Kissei Pharmaceutical
MS
Masanori Suzuki
Representative Director, President & CEO
KA
Kazunori Araki
Director, Senior Managing Executive Officer
HY
Hiroshi Yamada
Director, Senior Managing Executive Officer
TH
Tatsuya Higashi
Director, Managing Executive Officer
YI
Yoshinori Ishihara
Director, Managing Executive Officer
TM
Takeshi Matsuzaki
Director, Managing Executive Officer
YO
Yukihiro Ochi
Director
YO
Yoshihiro Oyamada
Director
YK
Yoshihiko Kawamura
Standing Corporate Auditor
MO
Masahiko Oka
Corporate Auditor